ClinicalTrials.gg
RecruitingNCT05850130ACUPOXUpdated Sep 11, 2026

Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

An interventional study of Acupuncture intervention and No acupuncture in Colorectal Cancer, Liver Cancer and Gastric Cancer, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. Recruiting at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Colorectal Neoplasms by GERCOR - Multidisciplinary Oncology Cooperative Group — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · GERCOR - Multidisciplinary Oncology Cooperative Group.

Planned enrollment
6th of 16
182 · median 136
Started
2023
the only one that year
No phase
Only one
of the 23
Registered
22nd of 23
by date

Among the 23 studies in Colorectal Neoplasms by GERCOR - Multidisciplinary Oncology Cooperative Group, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is the only one with no phase, and was the 22nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 23 studies in Colorectal Neoplasms by GERCOR - Multidisciplinary Oncology Cooperative Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Colorectal Neoplasms by GERCOR - Multidisciplinary Oncology Cooperative Group, or all of them as a file.
02

Study summary

ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with gastro-intestinal solid tumors who discontinued oxaliplatin-containing chemotherapy.

Read the detailed description

In this design, patients will be randomized into two-arm (2:1 allocation) Cohort 1: a comparative randomized design (Arm A = Experimental vs Arm B = Control) or included into Cohort 2: a single arm design.

The study follows the Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) guideline.

All acupuncture interventions will be conducted by a physician acupuncturist. If the patient will be getting chemotherapy (that is optional treatment) during the study duration, acupuncture will be given at the same time.

03

Conditions studied

  • Colorectal Cancer
  • Liver Cancer
  • Gastric Cancer
  • Pancreas Cancer
  • Esophagus Cancer

Keywords

  • acupuncture
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient is included if:

  1. Agree to participate in this study, voluntarily signing a written form,
  2. Aged ≥ 18 years,
  3. Have an performance status (ECOG PS) of 0-2,
  4. Have or cytologically confirmed gastro-intestinal solid tumors, previously treated with any oxaliplatin-based chemotherapy; a concomitant radio-chemotherapy course is allowed,
  5. Had the last oxaliplatin infusion > 2 weeks before inclusion,
  6. Present OIPN with a numerical rating score (NRS) ≥ 4/10 at inclusion,
  7. Currently receiving or recently completed chemotherapy (adjuvant, , or advanced stage). Patients may receive current chemotherapy treatment (e.g., with FOLFIRI, 5-fluorouracil, bevacizumab regimens), excluding platinum salts and taxane-based regimens during the study,
  8. Are able to understand/read French,
  9. Are registered in a national health care system (PUMa - Protection Universelle Maladie included),

Exclusion criteria

Exclusion Criteria

Patients is excluded if:

  1. Had acupuncture sessions for the prevention of chemotherapy-induced side effects in the last 3 months prior to inclusion,
  2. Had previous and/or current chemotherapy treatments with taxane-based regimens (e.g., the TFOX regimen [docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil]),
  3. Have a history of preexisting clinically-significant peripheral neuropathy due to any cause other than chemotherapy (borrelia infection, infection, hereditary factors, tumor compression, nutritional deprivation, alcohol, diabetes, etc.),
  4. Have a recent history (within 4 weeks prior to start of acupuncture) of abusing alcohol, prescription, or illicit drugs (including cannabinoid), or medical, psychological, or social conditions that may interfere with the patient's compliance with the study intervention, NB: The patient should be informed that drinking alcohol should be avoided while on study.
  5. Have any other condition that, in the opinion of the investigator, is unstable or could jeopardize the safety of the patient and her/his compliance during the study,
  6. Have limb edema of grade 3 ( v5),
  7. Had phytotherapy within 2 weeks before a week 1-14 intervention,
  8. Are pregnant or breastfeeding,
  9. Are under the tutorship or guardianship of the state or in custody of the justice system.
  10. Had photobiomodulation therapy sessions in the last month prior to inclusion (this therapy is not permitted during the study)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Arm A

    6 weeks of acupuncture once a week. At week 7, patients will be assessed for the primary endpoint Then ,the patient may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist.

    Other: Acupuncture intervention

  • Active comparator
    Arm B

    6 weeks without acupuncture. At week 7, patients will be assessed for the primary endpoint. Then, the patient will receive or not acupuncture intervention: * A mandatory acupuncture once a week if the patient' NRS global score at week 7 is ≥ 4 . * No acupuncture if the patient' NRS global score at week 7 is \<4,

    Other: No acupuncture

Interventions

  • OtherAcupuncture intervention

    6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints. After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist.

  • OtherNo acupuncture

    The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).

06

What researchers measure

Primary outcomes

  1. 2-point improvement in the global NRS

    The primary endpoint is a 2-point improvement in the global numeric rating scale (NRS) score from randomization/inclusion defined by the patient at week 7. The 11-point NRS range from 0 to 10 (0 = no symptom, 1-3 = mild, 4-6 = moderate, 7-10 = severe).

    Time frame: Week 7

Secondary outcomes

  1. Numerical Rating Scale (NRS) score

    A success of acupuncture for the patient is defined by a 2-point improvement on the overall NRS between baseline and week 7 after the randomization of Cohort 1 and inclusion of Cohort 2.

    Time frame: Week 7

  2. Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy twenty-item scale (QLQ-CIPN20) questionnaire

    The EORTC QLQ-CIPN20 questionnaire consists of 20 items that are divided into 3 subscales: the items in CIPN20 have been divided into three subscales. The sensory subscale consists of items 1, 2, 3, 4, 5, 6, 9, 10, and 18; motor: items 7, 8, 11, 12, 13, 14, 15, and 19; and autonomic nerve-related: items 16, 17, and 20. Each subscale is summed and linearly transformed to a score that can range from 0 to 100, where higher scores represent greater CIPN symptom severity. Patients will rate their experience for each symptom during the previous week using scores from 1 (not at all) to 4 (very much).

    Time frame: Assess at baseline, at week 7, 14, and at 6 months

  3. Brief Pain Inventory (BPI) score

    This 9-item BPI self-reported questionnaire provides information on the intensity of pain and the degree to which pain interferes with function. Pain is rated over the prior week and the degree to which the pain interferes with activities using a 0 to 10-point scale.

    Time frame: Assess at baseline, at week 7, 14, and at 6 months

  4. Peripheral sensory neuropathy grading scale

    Severity of the peripheral sensory neuropathies will be classified using a 4-point scale ranging from grade 1 to grade 4 per criteria established in NCI CTCAE v. 5.0.

    Time frame: Assess at baseline, at each intervention visit, at week 7, 14, and at 6 months

07

Study locations

9 of 15 sites recruiting
  • CH Amiens-Picardie
    Amiens, France
    Recruiting
    • Vincent HAUTEFEUILLE, MD · Contact
  • CHU de Caen
    Caen, France
    Not yet recruiting
    • Adeline PASDELOUP, MD · Contact
  • Centre intercommunal de Créteil
    Créteil, France
    Recruiting
    • Isabelle COJEAN ZELEK, MD · Contact
    • Isabelle COJEAN ZELEK, MD · Principal investigator
  • Hôpital Henri Mondor
    Créteil, France
    Recruiting
    • emmanuelle KEMPF, MD · Contact
    • Emmanuelle KEMPF, MD · Principal investigator
  • Ghm - Institut Daniel Hollard
    Grenoble, France
    Recruiting
    • Camille HERVE, MD · Contact
    • Camille HERVE, MD · Principal investigator
  • CH Lille
    Lille, France
    Not yet recruiting
    • Anne PLOQUIN, MD · Contact
  • Centre Hospitalier Universitaire de Nimes - Site de Caremeau
    Nîmes, France
    Recruiting
    • Thomas BORDERIE, MD · Contact
  • Hôpital Bichat
    Paris, France
    Not yet recruiting
    • Gaël GOUJON, MD · Contact
  • Hôpital Pitié Salpêtrière
    Paris, France
    Recruiting
    • Jean Baptiste BACHET, MD · Contact
    • Jean Baptiste BACHET, MD · Principal investigator
  • Hôpital Saint Antoine
    Paris, France
    Recruiting
    • Hélène BOUSSION, MD · Contact
    • Hélène BOUSSION, MD · Principal investigator
  • Institut Curie-Paris
    Paris, France
    Recruiting
    • Celine LAOUISSET, Prof, MD · Contact
  • Saint-Louis Hospital
    Paris, France
    Not yet recruiting
    • Thomas APARICIO, Prof, MD · Contact
  • Curie Saint-Cloud
    Saint-Cloud, France
    Not yet recruiting
    • Aude GUILLAUMIN, MD · Contact
  • Bégin Military Teaching Hospital
    Saint-Mandé, France
    Not yet recruiting
    • Julie LAVOLE, MD · Contact
  • Paul Brousse Hospital
    Villejuif, France
    Recruiting
    • Pascal HAMMEL, Prof, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 35 months is close to that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 9, 2023
StartActual
Nov 22, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05850130
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Nov 22, 2023
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Marie Line GARCIA LARNICOL
Contact
regulatory.affairs@gecor.com.fr
0140298500
Emmanuelle Kempf, MD
principal investigator · Henri Mondor University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion